tbuckley/cabot-search huggingface dataset:
Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, <scp>COFAITH EAACI</scp> task force
Authors: Pablo Rodríguez del Río, Montserrat Álvaro‐Lozano, Stefania Arasi, Raphaëlle Bazire, Carmelo Escudero, Nandinee Patel, Monica Sandoval‐Ruballos, Marta Vazquez‐Ortiz, Anna Nowak‐Wegrzyn, Katharina Blümchen, Audrey Dunn Galvin, Antoine Deschildre, Matthew Greenhawt, Sabine Schnadt, Carmen Riggioni, Benjamin C. Remington, Paul Turner, Montserrat Fernandez Rivas
Journal: Allergy (2024)

Abstract Food allergy is a global public health problem that until recent years lacked any aetiological treatment supported by academy, industry and regulators. Food immunotherapy (AIT) is an evolving treatment option, supported by clinical practice and industry trial data. Recent AIT meta‐analyses have highlighted the difficulty in pooling safety and efficacy data from AIT trials, due to secondary heterogeneity in the study. An EAACI task force (CO‐FAITH) initiated by the Paediatric Section was created to focus on AIT efficacy outcomes for milk, egg and peanut allergy rather than in trial results. A systematic search and a narrative review of AIT controlled clinical trials and large case series was conducted. A total of 63 manuscripts met inclusion criteria, corresponding to 23, 21 and 22 studies of milk, egg and peanut AIT, respectively. The most common AIT efficacy outcome was desensitization, mostly defined as tolerating a maintenance phase dose, or reaching a particular dose upon successful exit oral food challenge (OFC). However, a large degree of heterogeneity was identified regarding the dose quantity defining this outcome. Sustained unresponsiveness and patient‐reported outcomes (e.g. quality of life) were explored less frequently, and to date have been most rigorously described for peanut AIT versus other allergens. Change in allergen threshold assessed by OFC remains the most common efficacy measure, but OFC methods suffer from heterogeneity and methodological disparity. This review has identified multiple heterogeneous outcomes related to measuring the efficacy of AIT. Efforts to better standardize and harmonize which outcomes, and how to measure them must be carried out to help in the clinical development of safe and efficacious food allergy treatments.
Reconstruction of Cystic Defects with Resorbable Membranes and “Shoelace” Sutures: A Case Series
Authors: Celestine Teo, Celestine Teo, Leonardo Saigo
Journal: International Journal of Surgery (2024)

Radicular cysts are one of the most commonly occurring cysts in the jaw, with an occurrence rate of 54.6% amongst odontogenic cysts. After removal of the cyst, there tends to be a large bony defect, resulting in a buccal concavity, especially when the buccal cortex has been eroded by the cyst. This compromises aesthetic outcomes where prosthodontics rehabilitation is considered in the future. Here we describe two cases of reconstruction of cystic defects with resorbable membranes, supported by a stable framework of “shoelace” sutures, with the objective of improving hard and soft tissue healing with minimal buccal collapse. This technique is useful in supporting resorbable membranes placed above the defect and can potentially reduce the extent of hard and soft tissue deficiency.
FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma
Authors: Thomas M. Anderson, Bryan H. Chang, Alexander C. Huang, Xiaowei Xu, Daniel Yoon, Catherine G. Shang, Rosemarie Mick, Erin Schubert, Suzanne McGettigan, Kristin Kreider, Wei Xu, E. John Wherry, Lynn M. Schuchter, Ravi K. Amaravadi, Tara C. Mitchell, Michael D. Farwell
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Immunologic response to anti–programmed cell death protein 1 (PD-1) therapy can occur rapidly with T-cell responses detectable in as little as one week. Given that activated immune cells are FDG avid, we hypothesized that an early FDG PET/CT obtained approximately 1 week after starting pembrolizumab could be used to visualize a metabolic flare (MF), with increased tumor FDG activity due to infiltration by activated immune cells, or a metabolic response (MR), due to tumor cell death, that would predict response. Patients and Methods: Nineteen patients with advanced melanoma scheduled to receive pembrolizumab were prospectively enrolled. FDG PET/CT imaging was performed at baseline and approximately 1 week after starting treatment. FDG PET/CT scans were evaluated for changes in maximum standardized uptake value (SUVmax) and thresholds were identified by ROC analysis; MF was defined as &amp;gt;70% increase in tumor SUVmax, and MR as &amp;gt;30% decrease in tumor SUVmax. Results: An MF or MR was identified in 6 of 11 (55%) responders and 0 of 8 (0%) nonresponders, with an objective response rate (ORR) of 100% in the MF-MR group and an ORR of 38% in the stable metabolism (SM) group. An MF or MR was associated with T-cell reinvigoration in the peripheral blood and immune infiltration in the tumor. Overall survival at 3 years was 83% in the MF-MR group and 62% in the SM group. Median progression-free survival (PFS) was &amp;gt;38 months (median not reached) in the MF-MR group and 2.8 months (95% confidence interval, 0.3–5.2) in the SM group (P = 0.017). Conclusions: Early FDG PET/CT can identify metabolic changes in melanoma metastases that are potentially predictive of response to pembrolizumab and significantly correlated with PFS.
Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives
Authors: Jiaxi Liu, Yongya Wu, Sha Meng, Ping Xu, Shutong Li, Yong Li, Xiuying Hu, Liang Ouyang, Guan Wang
Journal: Molecular Cancer (2024)

Abstract Eukaryotic cells engage in autophagy, an internal process of self-degradation through lysosomes. Autophagy can be classified as selective or non-selective depending on the way it chooses to degrade substrates. During the process of selective autophagy, damaged and/or redundant organelles like mitochondria, peroxisomes, ribosomes, endoplasmic reticulum (ER), lysosomes, nuclei, proteasomes, and lipid droplets are selectively recycled. Specific cargo is delivered to autophagosomes by specific receptors, isolated and engulfed. Selective autophagy dysfunction is closely linked with cancers, neurodegenerative diseases, metabolic disorders, heart failure, etc. Through reviewing latest research, this review summarized molecular markers and important signaling pathways for selective autophagy, and its significant role in cancers. Moreover, we conducted a comprehensive analysis of small-molecule compounds targeting selective autophagy for their potential application in anti-tumor therapy, elucidating the underlying mechanisms involved. This review aims to supply important scientific references and development directions for the biological mechanisms and drug discovery of anti-tumor targeting selective autophagy in the future.
Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort
Authors: Hannah L Cornman, Katherine A Whang, Emily Ma, Prachi Aggarwal, Anusha Kambala, Sriya V Reddy, Sylvie Gabriel, Shawn G Kwatra
Journal: British Journal of Dermatology (2024)

We performed a cross-sectional study using validated survey instruments, finding severe pruritus, reduced quality of life (QoL) and a significant mental health burden in a diverse cohort of patients with prurigo nodularis (PN) from the USA. Itch severity and QoL scores were comparable to those found in European populations, aside from ItchyQoL scores (higher scores in this US cohort). Black patients reported higher itch intensity scores than White patients. More than 37% of patients met the cutoff for severe depression, but only 26% had a clinical diagnosis of depression. Dermatologists should be aware that PN extends beyond severe pruritus, consider screening for psychiatric comorbidities and address other concerns that affect QoL as needed.
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
Authors: Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue
Journal: Clinical and Molecular Hepatology (2024)

Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with biopsy-confirmed MASLD using data from a multicenter study.
<scp>AllergoOncology</scp>: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint <scp>EAACI‐EANO</scp> position paper
Authors: Michelle C. Turner, Urszula Radzikowska, Denisa E. Ferastraoaru, Mariona Pascal, Pieter Wesseling, Alexandra McCraw, Claudine Backes, Heather J. Bax, Christoph Bergmann, Rodolfo Bianchini, Luigi Cari, Leticia de las Vecillas, Elena Izquierdo, Frida Lind‐Holm Mogensen, Alessandro Michelucci, Petr V. Nazarov, Simone P. Niclou, Giuseppe Nocentini, Markus Ollert, Matthias Preusser, Nataliya Rohr‐Udilova, Andrea Scafidi, Reka Toth, Mieke Van Hemelrijck, Michael Weller, Uta Jappe, Maria M. Escribese, Erika Jensen‐Jarolim, Sophia N. Karagiannis, Aurélie Poli
Journal: Allergy (2024)

Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune-glioma interactions to ultimately improve patient prognosis and survival.
Associations Between General and Specific Mental Health Conditions in Young Adulthood and Cardiometabolic Complications in Middle Adulthood: A 40-Year Longitudinal Familial Coaggregation Study of 672,823 Swedish Individuals
Authors: Cen Chen, Zheng Chang, Ralf Kuja-Halkola, Brian M. D’Onofrio, Henrik Larsson, Pontus Andell, Paul Lichtenstein, Erik Pettersson
Journal: American Journal of Psychiatry (2024)

Objective: Most mental disorders, when examined individually, are associated with an increased risk of cardiometabolic complications. However, these associations might be attributed to a general liability to psychopathology or confounded by unmeasured familial factors. The authors investigated the association between psychiatric conditions in young adulthood and the risk of cardiometabolic complications in middle adulthood, up to 40 years later. Methods: This cohort study (N=672,823) identified all individuals and their siblings born in Sweden between 1955 and 1962 and followed the cohort through 2013. Logistic regression models were used to estimate the bivariate associations between 10 psychiatric conditions or criminal convictions and five cardiometabolic complications in individuals. A general factor model was used to identify general, internalizing, externalizing, and psychotic factors based on the comorbidity among psychiatric conditions and criminal convictions. The cardiometabolic complications were then regressed on the latent general factor and three uncorrelated specific factors within a structural equation modeling framework in individuals and across sibling pairs. Results: Each psychiatric condition significantly increased the risk of cardiometabolic complications. These associations appeared nonspecific, as multivariate models indicated that most were attributable to the general factor of psychopathology, rather than to specific psychiatric conditions. There were no or only small associations between individuals' general psychopathology and their siblings' cardiometabolic complications. The same pattern was evident for the specific internalizing and psychotic factors. Conclusions: Associations between mental disorders in early life and later long-term risk of cardiometabolic complications appeared to be attributable to a general liability to psychopathology. Familial coaggregation analyses suggested that the elevated risk could not be attributed to confounders shared within families. One possibility is that lifestyle-based interventions may reduce the risk of later cardiometabolic complications for patients with several mental disorders.
Normalization of Fronto-Parietal Activation by Cognitive-Behavioral Therapy in Unmedicated Pediatric Patients With Anxiety Disorders
Authors: Simone P. Haller, Julia O. Linke, Hannah L. Grassie, Emily L. Jones, David Pagliaccio, Anita Harrewijn, Lauren K. White, Reut Naim, Rany Abend, Ajitha Mallidi, Erin Berman, Krystal M. Lewis, Katharina Kircanski, Nathan A. Fox, Wendy K. Silverman, Ned H. Kalin, Yair Bar-Haim, Melissa A. Brotman
Journal: American Journal of Psychiatry (2024)

Objective: Anxiety disorders are prevalent among youths and are often highly impairing. Cognitive-behavioral therapy (CBT) is an effective first-line treatment. The authors investigated the brain mechanisms associated with symptom change following CBT. Methods: Unmedicated youths diagnosed with an anxiety disorder underwent 12 weeks of CBT as part of two randomized clinical trials testing the efficacy of adjunctive computerized cognitive training. Across both trials, participants completed a threat-processing task during functional MRI before and after treatment. Age-matched healthy comparison youths completed two scans over the same time span. The mean age of the samples was 13.20 years (SD=2.68); 41% were male (youths with anxiety disorders, N=69; healthy comparison youths, N=62). An additional sample including youths at temperamental risk for anxiety (N=87; mean age, 10.51 years [SD=0.43]; 41% male) was utilized to test the stability of anxiety-related neural differences in the absence of treatment. Whole-brain regional activation changes (thresholded at p<0.001) were examined using task-based blood-oxygen-level-dependent response. Results: Before treatment, patients with an anxiety disorder exhibited altered activation in fronto-parietal attention networks and limbic regions relative to healthy comparison children across all task conditions. Fronto-parietal hyperactivation normalized over the course of treatment, whereas limbic responses remained elevated after treatment. In the at-risk sample, overlapping clusters emerged between regions showing stable associations with anxiety over time and regions showing treatment-related changes. Conclusions: Activation in fronto-parietal networks may normalize after CBT in unmedicated pediatric anxiety patients. Limbic regions may be less amenable to acute CBT effects. Findings from the at-risk sample suggest that treatment-related changes may not be attributed solely to the passage of time.
Disulfiram ameliorates STING/MITA-dependent inflammation and autoimmunity by targeting RNF115
Authors: Zhi-Dong Zhang, Chang-Rui Shi, Fang-Xu Li, Hu Gan, Yanhong Wei, Qianhui Zhang, Xin Shuai, Min Chen, Yu-Lin Lin, Tian-Chen Xiong, Xiaoqi Chen, Bo Zhong, Dandan Lin
Journal: Cellular and Molecular Immunology (2024)
The inhibition of several components of terminal complement pathway results in <scp>C3</scp> binding to <scp>PNH</scp> red blood cells
Authors: Michela Sica, Rosario Notaro
Journal: American Journal of Hematology (2024)

Graphical Abstract C3 binding on PNH red blood cells after in vitro complement activation in normal and terminal complement depleted (∆5, ∆6, ∆9) sera: C3 binding, and the subsequent extravascular hemolysis, happens anytime there is a block of a component of the terminal complement pathway.
Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation
Authors: Siddharth M. Patel, Eugene Braunwald, Jan Steffel, Giuseppe Boriani, Michael G. Palazzolo, Elliott M. Antman, Erin A. Bohula, Anthony P. Carnicelli, Stuart J. Connolly, John W. Eikelboom, Baris Gencer, Christopher B. Granger, David A. Morrow, Manesh R. Patel, Lars Wallentin, Christian T. Ruff, Robert P. Giugliano
Journal: Circulation (2024)

The efficacy and safety of non-vitamin-K antagonist oral anticoagulants (NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain uncertain.
Impact of climate change on atopic dermatitis: A review by the International Eczema Council
Authors: Sheng‐Pei Wang, Nicholas Stefanovic, Raquel L. Orfali, Valeria Aoki, Sara J. Brown, Sandipan Dhar, Lawrence F. Eichenfield, Carsten Flohr, Alex Ha, Camilo Mora, Jenny E. Murase, Misha Rosenbach, Sahana M. Srinivas, Jacob P. Thyssen, Maria L. Wei, Alan D. Irvine, Katrina Abuabara
Journal: Allergy (2024)

Atopic dermatitis (AD), the most burdensome skin condition worldwide, is influenced by climatic factors and air pollution; however, the impact of increasing climatic hazards on AD remains poorly characterized. Leveraging an existing framework for 10 climatic hazards related to greenhouse gas emissions, we identified 18 studies with evidence for an impact on AD through a systematic search. Most climatic hazards had evidence for aggravation of AD the impact ranged from direct effects like particulate matter-induced AD exacerbations from wildfires to the potential for indirect effects like drought-induced food insecurity and migration. We then created maps comparing the past, present, and future projected burden of climatic hazards to global AD prevalence data. Data are lacking, especially from those regions most likely to experience more climatic hazards. We highlight gaps important for future research: understanding the synergistic impacts of climatic hazards on AD, long-term disease activity, the differential impact on vulnerable populations, and how basic mechanisms explain population-level trends.
Association of Survival With Immune-Related Adverse Events—Time to Consider the Duration of Treatment
Authors: Yu Fujiwara, Alessio Cortellini, Abdul Rafeh Naqash
Journal: JAMA Dermatology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Education and Information to Improve Cardiovascular Health—Reply
Authors: Gloria Santos-Beneit, Rodrigo Fernández-Jiménez, Valentín Fuster
Journal: JAMA Cardiology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Caution With Casual Causal Language—Reply
Authors: Daniel T. Myran, Marco Solmi, Peter Tanuseputro
Journal: JAMA Psychiatry (2024)

In Reply We thank Leung and Weisskopf for their comment on our article.1 Their main point is that we inappropriately used causal language when discussing our findings. We outline 2 important considerations on this point below.
Advancements and mechanisms of stem cell-based therapies for spinal cord injury in animals
Authors: Bhabesh Mili, Om Prakash Choudhary
Journal: International Journal of Surgery (2024)

Spinal cord injury (SCI) is a neurodegenerative disorder of the central nervous system (CNS) that can lead to permanent loss of sensation and voluntary movement beyond the affected area. Extensive preclinical and clinical trials have been conducted to evaluate the safety and effectiveness of stem cells for the treatment of various CNS diseases or disorders, including SCI. However, several challenges hinder nerve cell regeneration in the injured spinal cord, such as extensive cell loss, limited neural cell regeneration capacity, axonal disruption, and the presence of growth-inhibiting molecules, particularly astroglial scarring or glial scars at the injury site in chronic cases. These obstacles pose significant challenges for physicians in restoring normal motor and sensory nerve function in both humans and animals following SCI. This review focuses on SCI pathogenesis, the mechanisms underlying the therapeutic potential of Mesenchymal Stem Cells (MSCs) in SCI, and the potential of stem cell-based therapies as promising avenues for treatment. This review article also included relevant preclinical and clinical data from animal studies.